Publication – August 24, 2016
August 24, 2016

Diosmetin: An Anti-Leukemic Flavonoid Targeting the Estrogen Receptor β

Abstract Acute myeloid leukemia (AML) is an aggressive hematological malignancy resulting from the accumulation of immature myeloid cells in the peripheral blood and bone
marrow. It is associated with poor prognosis, especially in older patients where the 2-year survival rate is approximately 10%. Leukemia stem cells (LSCs) are the cells responsible for
AML development. To prevent relapse and improve patient prognosis, new therapies targeting LSCs are needed. Thus, to identify novel anti-AML agents, we created a unique

Leave a Reply